Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "LA"

9395 News Found

Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens
News | March 10, 2026

Neuland to launch commercial peptide facility in Hyderabad as global capacity tightens

The first of four planned modules at the new plant is expected to come online by summer 2026


Avio Smart teams up with Huwel Lifesciences to roll out next-gen molecular diagnostics in India
News | March 10, 2026

Avio Smart teams up with Huwel Lifesciences to roll out next-gen molecular diagnostics in India

Huwel’s diagnostic solutions leverage open RT-PCR system


Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer
Biotech | March 10, 2026

Relmada’s NDV-01 shows strong 12-month results in hard-to-treat bladder cancer

The study showed a 76% complete response (CR) rate at 12 months, rising to 95% at any time for high-risk NMIBC patients


DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial
Clinical Trials | March 09, 2026

DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial

DiaMedica said it plans to launch the trial later in 2026


SEQSTER launches 1-Click DataLake, unlocking real-world health data from 150M+ patients
Digitisation | March 09, 2026

SEQSTER launches 1-Click DataLake, unlocking real-world health data from 150M+ patients

The company says those insights can power advanced analytics and real-world evidence (RWE), helping researchers improve trial design, study feasibility, and recruitment strategies


FDA nod to groundbreaking combo therapy for relapsed multiple myeloma
News | March 07, 2026

FDA nod to groundbreaking combo therapy for relapsed multiple myeloma

This new treatment option can redefine how we approach RRMM treatment by giving healthcare providers a regimen with improvement in PFS and OS and a well-characterized safety profile


argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis
Clinical Trials | March 06, 2026

argenx reports breakthrough Phase 3 results for VYVGART in ocular myasthenia gravis

The trial met its primary endpoint, showing statistically significant improvements in Myasthenia Impairment Index (MGII) Patient-Reported Outcome (PRO) ocular scores at Week 4


CordenPharma expands boulder presence with 64,000-Sq-Ft Lease at BioMed Realty’s Flatiron Park
News | March 06, 2026

CordenPharma expands boulder presence with 64,000-Sq-Ft Lease at BioMed Realty’s Flatiron Park

The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant